New HIV shot candidates enter first human safety tests

NCT ID NCT06012136

Completed Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This early-stage trial tests the safety and tolerability of two experimental injectable drugs (capsid inhibitors) in 85 healthy adults. Participants receive a single dose or multiple doses of the drug or a placebo. The goal is to see if these drugs are safe enough to study further as a potential long-acting HIV treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VH4004280 and VH4011499 (capsid inhibitors)
What this could lead to: If successful, this could lead to a new long-acting injectable option for controlling HIV, reducing the need for daily pills.
What could go wrong: This is a very early Phase 1 safety study in healthy people, not those with HIV. It is too soon to know if these drugs will work against HIV or be safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Las Vegas, Nevada, 89113, United States
GSK Investigational Site

Austin, Texas, 78744, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.